Profiling microRNA from nephrectomy and biopsy specimens: predictors of progression and survival in clear cell renal cell carcinoma.

Autor: Kowalik CG; Department of Urology, Lahey Hospital and Medical Center, Burlington, MA, USA., Palmer DA; Department of Urology, Lahey Hospital and Medical Center, Burlington, MA, USA., Sullivan TB; Department of Translational Research - Ian C. Summerhayes Cell and Molecular Biology Laboratory, Lahey Hospital and Medical Center, Burlington, MA, USA., Teebagy PA; Department of Translational Research - Ian C. Summerhayes Cell and Molecular Biology Laboratory, Lahey Hospital and Medical Center, Burlington, MA, USA., Dugan JM; Department of Pathology, Lahey Hospital and Medical Center, Burlington, MA, USA., Libertino JA; Department of Urology, Lahey Hospital and Medical Center, Burlington, MA, USA., Burks EJ; Department of Pathology, Lahey Hospital and Medical Center, Burlington, MA, USA., Canes D; Department of Urology, Lahey Hospital and Medical Center, Burlington, MA, USA., Rieger-Christ KM; Department of Urology, Lahey Hospital and Medical Center, Burlington, MA, USA.; Department of Translational Research - Ian C. Summerhayes Cell and Molecular Biology Laboratory, Lahey Hospital and Medical Center, Burlington, MA, USA.
Jazyk: angličtina
Zdroj: BJU international [BJU Int] 2017 Sep; Vol. 120 (3), pp. 428-440. Date of Electronic Publication: 2017 May 18.
DOI: 10.1111/bju.13886
Abstrakt: Objective: To identify microRNA (miRNA) characteristic of metastatic clear cell renal cell carcinoma (ccRCC) and those indicative of cancer-specific survival (CSS) in nephrectomy and biopsy specimens. We also sought to determine if a miRNA panel could differentiate benign from ccRCC tissue.
Materials and Methods: RNA was isolated from nephrectomy and kidney biopsy specimens (n = 156 and n = 46, respectively). Samples were grouped: benign, non-progressive, and progressive ccRCC. MiRNAs were profiled by microarray and validated by quantitative reverse transcription-polymerase chain reaction. Biomarker signatures were developed to predict cancer status in nephrectomy and biopsy specimens. CSS was examined using Kaplan-Meier and Cox proportional hazards analyses.
Results: Microarray analysis revealed 20 differentially expressed miRNAs comparing non-progressive with progressive tumours. A biomarker signature validated in nephrectomy specimens had a sensitivity of 86.7% and a specificity of 92.9% for differentiating benign and ccRCC specimens. A second signature differentiated non-progressive vs progressive ccRCC with a sensitivity of 93.8% and a specificity of 83.3%. These biomarkers also discriminated cancer status in biopsy specimens. Levels of miR-10a-5p, -10b-5p, and -223-3p were associated with CSS.
Conclusion: This study identified miRNAs differentially expressed in ccRCC samples; as well as those correlating with CSS. Biomarkers identified in this study have the potential to identify patients who are likely to have progressive ccRCC, and although preliminary, these results may aid in differentiating aggressive and indolent ccRCC based on biopsy specimens.
(© 2017 The Authors BJU International © 2017 BJU International Published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje